

TLR4 promoter rs1927914 variant contribute to the susceptibility of esophageal squamous cell carcinoma in Chinese population

Jiaying Li^{1,2}, Hongjiao Wu², Hui Gao¹, Ruihuan Kou³, Yuning Xie^{1,2}, Zhi Zhang³, Xuemei Zhang^{Corresp. 2}

¹ School of Public Health, North China University of Science and Technology, Tangshan, China

² College of Life Science, North China University of Science and Technology, Tangshan, China

³ Affiliated Tangshan Gongren Hospital, North China University of Science and Technology, Tangshan, China

Corresponding Author: Xuemei Zhang

Email address: jyxuemei@gmail.com

Background. Toll-like receptor 4 (TLR4), as a key regulator of both innate and acquired immunity has been linked with the development of various cancers. Although the association between TLR4 rs1927914 gene polymorphism and cancer have been reported, studies on genetic susceptibility to esophageal cancer have not been reported. Thus, this study aims to analyze the relationship between genetic variations TLR4 rs1927914 and the risk of esophageal cancer. **Methods.** This study adopts case-control research strategy to investigate the association between genetic variation of TLR4 and esophageal squamous cell carcinoma (ESCC) risk and includes 480 ESCC patients and 480 health controls. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used to genotype TLR4 rs1927914 polymorphism. Taqman probe method was used to determine the genotypes of TLR4 rs11536891 and rs7873784 variants. The relationship between TLR4 genetic variation and ESCC risk was analyzed by Logistic regression model by calculating the odds ratio (OR) and 95% confidence interval (95%CI). **Results.** Compared with TLR4 rs1927914AA genotype carriers, GG carriers had a lower ESCC risk (OR = 0.59, 95%CI = 0.38-0.93, P = 0.023). Stratification analysis by age showed that TLR4 rs1927914GG could affect the risk of ESCC in elderly people (OR = 0.59, 95%CI = 0.36-0.97). Smoking stratification analysis indicated that rs1927914 GG carriers were related to ESCC susceptibility among non-smokers (OR = 0.36, 95%CI = 0.18-0.73). We found that TLR4 rs7873784 (G>C) and rs11536891 (T>C) conforms to complete genetic linkage, and their genotype distributions of these two SNPs among ESCC patients and normal controls were not statistically significant (P>0.05). Dual luciferase reporter assay suggested that TLR4 rs1927914 G allele reporter gene activity was 1.76-fold higher than A allele in KYSE30 ESCC cells. **Conclusion.** TLR4 rs1927914 variant contribute to the ESCC risk by effecting the promoter activity.

1 **TLR4 promoter rs1927914 variant contribute to the susceptibility of esophageal squamous**
2 **cell carcinoma in Chinese population**

3

4 Jiaying Li^{1,2}, Hongjiao Wu², Hui Gao¹, Ruihuan Kou³, Yuning Xie^{1,2}, Zhi Zhang³, Xuemei
5 Zhang^{1,2}

6

7 ¹School of Public Health, North China University of Science and Technology, Tangshan, Hebei,
8 China

9 ²College of Life Science, North China University of Science and Technology, Tangshan, Hebei,
10 China

11 ³Affiliated Tangshan Gongren Hospital, North China University of Science and Technology,
12 Tangshan, Hebei, China

13

14 Corresponding Author:

15 Xuemei Zhang^{1,2}

16 No. 21 Bohai Avenue, Caofeidian District, Tangshan/Hebei, 063009, China

17 Email address: jyxuemei@gmail.com

18

19

20

22 Abstract

23 **Background.** Toll-like receptor 4 (TLR4), as a key regulator of both innate and acquired
24 immunity has been linked with the development of various cancers. Although the association
25 between TLR4 rs1927914 gene polymorphism and cancer have been reported, studies on genetic
26 susceptibility to esophageal cancer have not been reported. Thus, this study aims to analyze the
27 relationship between genetic variations TLR4 rs1927914 and the risk of esophageal cancer.

28 **Methods.** This study adopts case-control research strategy to investigate the association between
29 genetic variation of TLR4 and esophageal squamous cell carcinoma (ESCC) risk and includes
30 480 ESCC patients and 480 health controls. Polymerase chain reaction-restriction fragment
31 length polymorphism (PCR-RFLP) was used to genotype TLR4 rs1927914 polymorphism.
32 Taqman probe method was used to determine the genotypes of TLR4 rs11536891 and rs7873784
33 variants. The relationship between TLR4 genetic variation and ESCC risk was analyzed by
34 Logistic regression model by calculating the odds ratio (*OR*) and 95% confidence interval
35 (*95%CI*).

36 **Results.** Compared with TLR4 rs1927914AA genotype carriers, GG carriers had a lower ESCC
37 risk (*OR* = 0.59, *95%CI* = 0.38-0.93, *P* = 0.023). Stratification analysis by age showed that TLR4
38 rs1927914GG could affect the risk of ESCC in elderly people (*OR* = 0.59, *95%CI* = 0.36-0.97).
39 Smoking stratification analysis indicated that rs1927914 GG carriers were related to ESCC
40 susceptibility among non-smokers (*OR* = 0.36, *95%CI* = 0.18-0.73). We found that TLR4
41 rs7873784 (G>C) and rs11536891 (T>C) conforms to complete genetic linkage, and their
42 genotype distributions of these two SNPs among ESCC patients and normal controls were not
43 statistically significant (*P*>0.05). Dual luciferase reporter assay suggested that TLR4 rs1927914
44 G allele reporter gene activity was 1.76-fold higher than A allele in KYSE30 ESCC cells.

45 **Conclusion.** TLR4 rs1927914 variant contribute to the ESCC risk by effecting the promoter
46 activity.

47

48 **Keyword:** TLR4, Esophageal squamous cell carcinoma, Single nucleotide polymorphism, Innate
49 immune

50

51 **Introduction**

52 Esophageal cancer, as the sixth leading cause of cancer death, is one of the most common
53 malignant tumors worldwide(*Bray et al., 2018*). Esophageal cancer contains two common
54 histological types: esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma
55 (ESCC). There are clear differences between EAC and ESCC that affect their distribution and
56 incidence in the world(*Domper Arnal, Ferrández Arenas, & Lanas Arbeloa, 2015; Yang, Chen,*
57 *& Tu, 2016*). In China, most of the cases of esophageal cancer are squamous cell cancer(*Lin et*
58 *al., 2013*). ESCC is caused by environmental and genetic factors. Epidemiological studies have
59 reported that tobacco smoking, alcohol drinking, ingesting hot substances and so on played a role
60 in the development of ESCC(*Yu et al., 2018*). However, not all individuals who have been
61 exposed to these hazards eventually get ESCC. In recent years, genetic polymorphisms have
62 been reported to impact the development of esophageal cancer(*Hiyama et al., 2007; Yue et al.,*
63 *2017*).

64 The interaction between the immune system and malignant cells is an impact on
65 tumorigenicity(*Terme Tanchot, 2017*). On one hand, the immune system kills or clears malignant
66 transformed cells through a variety of mechanisms, on the other hand, malignant cells use a
67 variety of mechanisms to escape immune system-mediated rejection for their own development.
68 As the most studied pattern recognition receptor, Toll-like receptors (TLRs) can enhance the
69 innate immune response and stimulate antigen-derived cells such as dendritic cells, thus
70 activating the immune response of tumor-specific T cells and affecting the development of
71 tumors. TLR4, as the first identified mammal TLR, is widely expressed in the mammalian cell

72 surface. TLR4, as the main receptor for pathogen invasion, can not only recognize extracellular
73 antigens, but also respond to intracellular injury related factors, thus promoting the secretion of
74 inflammatory factors and interferon. Therefore, in the tumor microenvironment, TLR4 plays a
75 key part in tumor infiltration of immune cells or in cancer cells. Studies have shown that TLR4 is
76 overexpressed in a variety of malignant tumors and associated with poor prognosis in cancer
77 patients(*J. Li et al., 2017; Pandey, Chauhan, & Jain, 2018; Wang et al., 2017; Zhao et al., 2019*).

78 Single nucleotide polymorphisms (SNP) are one of the most common genetic variants in the
79 genome. Over the past decade, large-scale SNP analyses, known as genome-wide association
80 studies (GWAS), have provided a new way to identify genetic loci that may be associated with
81 the disease, such as cancer susceptibility, survival prognosis or drug response.

82 In view of the important role of TLR4 in tumors, we screened out three functional SNPs
83 located on TLR4 gene using bioinformatics methods and then performed a case-control study in
84 Chinese population to determine whether they were correlated with the occurrence of ESCC.

85

86 **Materials and methods**

87 **Study subjects**

88 In this study, 480 ESCC patients and 480 cancer-free controls were included. Cases were
89 recruited from Apr 2008 to Dec 2012 in Affiliated Tangshan Gongren Hospital and Tangshan
90 Renmin Hospital of North China University of Science and Technology (Tangshan, China).
91 Inclusion criteria: all patients were diagnosed as primary ESCC by histopathology; all specimen
92 were genetically unrelated Han Chinese; none of the patients had received radiotherapy or
93 chemotherapy. 480 healthy individuals were randomly recruited from the same region and
94 matched with cases on age and sex. All participants signed the written informed consent.
95 Institutional Review Board of North China University of Science and Technology had approved
96 the research (12-002).

97

98 TLR4 SNPs selection

99 In this study, we predicted the possible functional SNPs in the regulatory region of TLR4. All
100 included SNPs located in the promoter region or the 3' untranslated region with $MAF \geq 0.05$. For
101 the SNPs in the promoter region of TLR4, transcription factor binding capability was predicted
102 by TRANSFAC program. For the SNPs located in the 3' untranslated region, microRNA binding
103 ability was predicted using Web Server. Finally, TLR4 rs1927914 in the promoter region and
104 TLR4 rs11536891 and rs7873784 in the 3' untranslated region were selected for further
105 genotyping.

106

107 TLR4 genotyping

108 Each subject donated 2mL of peripheral blood. DNA was extracted using the blood DNA kit
109 provided by TIANGEN Biotech (Beijing). TLR4 rs1927914 genotyping was performed by the
110 Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The target
111 DNA fragment was amplified by PCR using the forward primer 5'-
112 TGACATGGAAAATGGAGAGATAGAGG-3' and reverse primer 5'-
113 GGACTATGATGGAGATTGAAAATGTGG-3'. PCR was performed using a 6 μ l reaction
114 system containing 0.05 μ M each primer, 10ng DNA, and 2 x Es Taq MasterMix (CW BIO,
115 Beijing, China). PCR procedure was 3 minutes at 95°C, followed by 32 cycles (30s at 95°C, 30s
116 at 56.5°C and 34s at 72°C) and 5 minutes at 72°C for final extension. TLR4 PCR products were
117 cut by *Nsi I* and verified with 3% agarose gel. TLR4 rs11536891 and rs7873784 variants were
118 genotyped using Taqman probe method. Taqman SNP genotyping assays C_31784036_10 and
119 C_29292008_10 were design by Thermo Fisher Scientific (Waltham, USA).

120

121 **Vector construction and site-directed mutation**

122 To analyze the effect of TLR4 promoter region genetic variation on transcriptional activity, we
123 used primers 5'-GGGGTACCCCGGATTGGAAGTGCTTGGAG-3' (with Kpn *I* recognition
124 site) (NEB, Ipswich, USA) and 5'-CTAGCTAGCTAGAAGAAGAAAACGCCTGC-3' (with
125 Nhe *I* recognition site) (NEB, Ipswich, USA) to amplify 1832bp fragment between the promoter
126 -1762 bp to 70bp of TLR4. The PCR product was cloned into pGL3-basic reporter vector
127 (Promega, Madison, USA). Based on the sequence results, we constructed pGL3-rs1927914A
128 plasmid. The template vectors (pGL3-rs1927914 A) were then used to obtain pGL3-rs1927914G
129 vector by site-specific mutagenesis reaction using site-specific mutation kit (TIANGEN, Beijing,
130 China). All constructs were verified by direct sequencing.

131

132 **Cell culture, Transfection and luciferase assay**

133 Esophageal carcinoma cells (KYSE30) were purchased from American Type Culture Collection
134 (ATCC). Cells were cultured in DMEM medium containing 10% FBS (Gibco, Vienna, Austria)
135 and 1% penicillin and streptomycin. Cells were seeded at a density of 3×10^5 cells/well in 24-
136 well plate to 70-80% confluence. Cells were co-transfected with different pGL3-Basic vectors
137 and pRL-SV40 using LipofectamineTM 2000 (Invitrogen, Carlsbad, USA). Luciferase activity
138 was detected by Dual Luciferase Reporter Assay. A 13 μ L of cell lysate was mixed with 25 μ L of
139 Luciferase Assay Reagent II, and Firefly luciferase activity was measured by GloMax 20/20
140 Luminometer. Then, 25 μ L of 1 \times Stop & Glo solution was added to determine Renilla luciferase
141 activity. The ratio of Firefly and Renilla luciferase activity was presented to the level of relative
142 luciferase activity. Independent experiments were performed three times.

143

144 **Statistical analysis**

145 In this study, all the research data were statistically analyzed using SPSS 23.0 (SPSS, Chicago,
146 USA). The differences of basic characteristics in cases and controls were tested by χ^2 test. The
147 Hardy-Weinberger equilibrium (HWE) of TLR4 polymorphisms in controls were tested by χ^2
148 test. The correlation between the genetic variants in TLR4 and the risk of esophageal cancer
149 were evaluated by *OR* and *95%CI*. The activity of luciferase reporter gene was compared by two
150 independent sample t-test. $P < 0.05$ indicated statistically significant.

151

152 **Results**

153 **Study subjects' general demographic characteristics**

154 The general information of all subjects was showed in Table 1. There were no significant
155 differences in age and gender between the cases and controls ($P > 0.05$). The proportion of
156 smokers in the case group was 64.4% and in control group was 30.6% ($P < 0.001$), indicating a
157 statistical difference. However, there were no statistically significant differences in cumulative
158 smoking among ESCC patients and healthy controls ($P = 0.149$).

159

160 **The influence of TLR4 variants on ESCC risk**

161 Table 2 showed the association of TLR4 rs1927914, rs11536891 and rs7873784 genotypes with
162 the susceptibility to esophageal cancer. Genotypes distribution of 3 SNPs among controls group
163 were consistent with the Hardy-Weinberg equilibrium (HWE), indicating that the selected
164 population was well representative. The genotypes frequencies of TLR4 rs1927914 AA, GA and
165 GG were 40.6% (195), 49.4% (237) and 10% (48) in cases and 35.2% (169), 49.6% (238) and
166 15.2% (73) in controls. Multivariate logistic regression analysis displayed that rs1927914 GG
167 genotype contributed to a decrease ESCC risk ($OR = 0.59$, $95\%CI = 0.38-0.93$, $P = 0.023$) when
168 compared with AA genotype. After genotyping TLR4 rs7873784 (G>C) and rs11536891 (T>C)

169 in 100 samples, we found that TLR4 rs7873784 and rs11536891 conforms to complete genetic
170 linkage. Based on this, in further study, we only genotyped TLR4 rs11536891. There was no
171 significant difference in the distribution of TLR4 rs11536891 genotypes in the case group and
172 the control group ($P>0.05$).

173

174 **Stratification analysis**

175 The stratification analysis by gender, age and smoking status was used to further explore the
176 interaction effect of genetic variation of TLR4 rs1927914 on ESCC risk (Table 3). When
177 stratified by gender, there was no significant correlation between genotypes of TLR4 rs1927914
178 and the esophageal cancer risk among males and females ($OR = 0.67$, $95\%CI = 0.41-1.09$; $OR =$
179 0.31 , $95\%CI = 0.09-1.11$). In the age stratification, median age (50-year) in controls was set as
180 cut-off value for all subjects. Our data showed that older subjects (age>50) with GG genotype
181 had a lower esophageal cancer risk than those with the AA genotype ($OR = 0.59$, $95\%CI = 0.36-$
182 0.97), but not among younger subjects($OR = 0.53$, $95\%CI = 0.18-1.55$). In a stratified analysis
183 based on smoking status, we found that the GG genotype was a protective factor among non-
184 smoker ($OR = 0.36$, $95\%CI = 0.18-0.73$), but not among smoker ($OR = 0.93$, $95\%CI = 0.49-$
185 1.76).

186

187 **Luciferase reporter gene activity detection**

188 For further verification, we assessed the effect of TLR4 rs1927914 genetic variation on
189 transcriptional activity. We transiently transfected the recombinant plasmid with rs1927914A
190 (pGL3-Basic-A), G allele (pGL3-Basic-G) or pGL3-Basic into KYSE30 cells together with an
191 internal control plasmid to detect the expression of luciferase activity, respectively. Reporter
192 gene assay result suggested that luciferase activity driven by TLR4 rs1927914 G allele was 1.76-
193 fold higher than TLR4 rs1927914 A allele ($P = 0.0043$) (Figure 1).

194

195 **Discussion**

196 Because the symptoms of esophageal cancer are not obvious in the early stage, most of the
197 patients are diagnosed in the middle and late stages and often accompanied by malnutrition. In
198 addition, due to the difficulty in surgical resection of partial lesions and poor effect of drug
199 treatment, the overall 5-year survival rate is around 19%(*Moral Moral et al., 2018*). Multiple
200 large clinical studies have shown that concurrent chemoradiotherapy (CCRT) can significantly
201 improve the local control rate and the overall survival rate of esophageal cancer(*Kang et al.,*
202 *2018; Takeda et al., 2018*). Therefore, CCRT is still the standard therapy for patients with locally
203 advanced esophageal cancer who cannot receive or refuse surgical treatment. However, CCRT is
204 not tolerated in patients with advanced age, severe cardiopulmonary complications or
205 malnutrition. In the past decade, targeted therapy has brought cancer treatment into the era of
206 precision therapy with its low toxic side effects and high therapeutic efficiency. The discovery of
207 EGFR, ALK and other driving genes in lung cancer provides an example for targeted therapy of
208 malignant tumors. Therefore, it is still necessary to look for potential molecular targets to guide
209 the clinical treatment of esophageal cancer.

210 TLRs are important components of inflammatory response by effecting on innate immune
211 response So far, it has been found that TLR family has 10 members. Studies have shown that
212 TLRs members play important roles in biological processes such as inflammatory response and
213 immune response, apoptosis and angiogenesis and are closely related to the development of
214 various cancers(*Belmont et al., 2014; Dajon, Iribarren, & Cremer, 2017; Garcia et al., 2016;*
215 *Paone et al., 2010; Vijay, 2018*). TLR4 gene locates in chromosome 9q32-33. TLR4 mRNA can
216 be polyadenylation at 3'UTR to produce 5432nt and 12853nt transcripts that both encode the
217 same 839aa protein. Kutikhin et al. found that the high expression of TLR4 in cancer tissues can
218 promote the metastasis and invasion of tumor cells, and it is not suppressed by the immune
219 system(*Davoodi, Hashemi, & Seow, 2013; Kutikhin et al., 2014*). Studies have shown that TLR4

220 is overexpressed in ESCC tissues and associated with poor prognosis in cancer patients(*X. Li et*
221 *al., 2018; Sato et al., 2020*). Therefore, reasonable inhibition of TLR4 gene expression is
222 conducive to disease recovery.

223 So far, several studies have found that TLR4 polymorphisms influence cancer
224 susceptibility, such as gastric cancer, myeloma and hepatocellular carcinoma(*Bagratiuni et al.,*
225 *2016; He et al., 2018; C. Huang et al., 2017*). In Chinese population, Huang et al. found that
226 there is a significantly decreased risk of gastric cancer in individuals carrying of the allele C for
227 the rs10116253 and allele T for the rs1927911 in TLR4(*L. Huang et al., 2014*). Similar results
228 were found in hepatocellular carcinoma(*Minmin et al., 2011*). Song et al. found that both TLR4
229 rs1927911 and rs11536858 polymorphism increased the susceptibility of prostate cancer in
230 Korean Men(*Song et al., 2009*). Our results showed that TLR4 rs1927914 variations affect the
231 risk of ESCC. Shi et al. reported that TLR4 rs1927914 genetic variations are correlated with the
232 hepatocellular carcinoma susceptibility(*Shi et al., 2017*). This result was in accordance with the
233 study of Minmin, which carriers with the heterozygous genotypes for the rs1927914 were
234 associated with HCC risk(*Minmin et al., 2011*). However, researchers didn't find the correlation
235 between TLR4 rs1927914 and lung and gastric cancer risk(*H. Huang et al., 2010; Wu et al.,*
236 *2020*). Therefore, it is suggested that TLR4 rs1927914 may be associated with occurrence of
237 ESCC. To verify the population data, we performed the luciferase reporter assay and provided
238 the evidence that rs1927914 G allele was associated with elevated transcriptional activity. TLR4
239 may promote esophageal cancer cell proliferation and inhibit apoptosis through different signal
240 transduction pathways. For example, inhibiting NF- κ B transcription factor expression inhibits
241 esophageal cancer progression(*Kohtz et al., 2019*). At present, there are few studies on the
242 correlation between TLR4 rs11536891 polymorphism and tumor and mainly focus on prostate
243 cancer or colorectal cancer. Song et al. found that TLR4 rs11536891 was not associated with
244 prostate cancer risk(*Song et al., 2009*), while Tsilidis et al. reported that TLR4 rs11536891 was
245 related to colorectal cancer risk(*Tsilidis et al., 2009*). In our previous study, TLR4 rs11536891
246 gene polymorphism was not correlated with lung cancer susceptibility(*Wu et al., 2020*). Our

247 study also showed that there was no correlation between TLR4 rs11536891 gene variation and
248 ESCC risk.

249 In addition to genetic factors, the development of tumors is also related to environmental
250 factors. Epidemiological studies suggest that smoking may induce esophageal cancer
251 risk(*DongThrift, 2017*). Thus, we performed stratification analysis for smoking status and found
252 TLR4 rs1927914 GG genotype carriers may decrease the risk of non-smokers, indicating that
253 tobacco smoking may be one of the risk factors for ESCC. This is consistent with the study of
254 Chen et al(*Chen et al., 2010*). Meanwhile, we found that GG genotype is a protective factor for
255 older subjects. These results suggest that the risk of ESCC is mainly caused by the combination
256 of environmental and genetic factors.

257

258 **Conclusion**

259 In summary, our report showed that TLR4 rs1927914 A>G polymorphism in the promoter
260 can affect the transcriptional activity of TLR4 further influence esophageal cancer susceptibility.

261

262 **Acknowledgments**

263 The authors thank all patients and control subjects for their participation.

264

265 **Funding**

266 This work was supported by Key Project of Natural Science Foundation of Hebei province
267 of China (H2017209233 to X. Zhang), Leader talent cultivation plan of innovation team in Hebei
268 province (LJRC001 to X. Zhang) and National Natural Science Foundation of China (81101483
269 to X. Zhang).

270

271 **Competing Interest**

272 All authors declare that they have no competing interests.

273

274 **Author contributions**

275 JL: acquisition, analysis, and interpretation of data; drafting the manuscript. HW, HG, RK,
276 XY: DNA extraction, data collection and analysis. ZZ collection of blood samples; acquisition
277 and interpretation of data. XZ: design of the work, analysis and interpretation of data, revision of
278 the article, final approval of the version to be published. All authors read and approved the final
279 manuscript.

280

281 **Human Ethics**

282 The following information was supplied relating to ethical approvals (i.e., approving body
283 and any reference numbers):

284 This research was approved by Institutional Review Board of North China University of
285 Science and Technology had approved the (12-002).

286

287 **Data Availability**

288 The following information was supplied regarding data availability:

289 The raw data are available as a Supplementary File.

290

291 **References**

- 292 Bagratuni T, Terpos E, Eleutherakis-Papaiakovou E, Kalapanida D, Gavriatopoulou M, Migkou
293 M, Liacos CI, Tasidou A, Matsouka C, Mparmparousi D, Dimopoulos MA, Kastritis E.
294 2016. TLR4/TIRAP polymorphisms are associated with progression and survival of
295 patients with symptomatic myeloma. *Br J Haematol* 172(1) 44-47 DOI
296 10.1111/bjh.13786.
- 297 Belmont L, Rabbe N, Antoine M, Cathelin D, Guignabert C, Kurie J, Cadranel J, Wislez M.
298 2014. Expression of TLR9 in tumor-infiltrating mononuclear cells enhances angiogenesis
299 and is associated with a worse survival in lung cancer. *Int J Cancer* 134(4) 765-777 DOI
300 10.1002/ijc.28413.
- 301 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. 2018. Global cancer statistics
302 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in
303 185 countries. *CA Cancer J Clin* 68(6) 394-424 DOI 10.3322/caac.21492.
- 304 Chen J, Zhang N, Wakai T, Wei L, He Y, Kumagai N, Kitsu K, Wang S, Akazawa K. 2010.
305 Effect of the interaction between the amount and duration of alcohol consumption and
306 tobacco smoking on the risk of esophageal cancer: A case-control study. *Exp Ther Med*
307 1(6) 991-997 DOI 10.3892/etm.2010.152.
- 308 Dajon M, Iribarren K, Cremer I. 2017. Toll-like receptor stimulation in cancer: A pro- and anti-
309 tumor double-edged sword. *Immunobiology* 222(1) 89-100 DOI
310 10.1016/j.imbio.2016.06.009.
- 311 Davoodi H, Hashemi SR, Seow HF. 2013. 5-Fluorouracil Induce the Expression of TLR4 on
312 HCT116 Colorectal Cancer Cell Line Expressing Different Variants of TLR4. *Iran J*
313 *Pharm Res* 12(2) 453-460.
- 314 Domper Arnal MJ, Ferrández Arenas Á, Lanas Arbeloa Á. 2015. Esophageal cancer: Risk

- 315 factors, screening and endoscopic treatment in Western and Eastern countries. *World J*
316 *Gastroenterol* 21(26) 7933-7943 DOI 10.3748/wjg.v21.i26.7933.
- 317 Dong J, Thrift AP. 2017. Alcohol, smoking and risk of oesophago-gastric cancer. *Best Pract Res*
318 *Clin Gastroenterol* 31(5) 509-517 DOI 10.1016/j.bpg.2017.09.002.
- 319 Garcia PV, Seiva FR, Carniato AP, de Mello Júnior W, Duran N, Macedo AM, de Oliveira AG,
320 Romih R, Nunes Ida S, Nunes Oda S, Fávares WJ. 2016. Increased toll-like receptors and
321 p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer:
322 mechanism of action of P-MAPA biological response modifier. *BMC Cancer* 16 422 DOI
323 10.1186/s12885-016-2474-z.
- 324 He B, Xu T, Pan B, Pan Y, Wang X, Dong J, Sun H, Xu X, Liu X, Wang S. 2018.
325 Polymorphisms of TGFBR1, TLR4 are associated with prognosis of gastric cancer in a
326 Chinese population. *Cancer Cell Int* 18 191 DOI 10.1186/s12935-018-0682-0.
- 327 Hiyama T, Yoshihara M, Tanaka S, Chayama K. 2007. Genetic polymorphisms and esophageal
328 cancer risk. *Int J Cancer* 121(8) 1643-1658 DOI 10.1002/ijc.23044.
- 329 Huang C, Zhang H, Bai R, Wang L, Lv J. 2017. A896G and C1196T Polymorphisms Within the
330 TLR4 Gene Abate Toll-Like Receptor 4-Mediated Signaling in HepG2 Cells. *DNA Cell*
331 *Biol* 36(11) 1029-1038 DOI 10.1089/dna.2017.3892.
- 332 Huang H, Wu J, Jin G, Zhang H, Ding Y, Hua Z, Zhou Y, Xue Y, Lu Y, Hu Z, Xu Y, Shen H.
333 2010. A 5'-flanking region polymorphism in toll-like receptor 4 is associated with gastric
334 cancer in a Chinese population. *J Biomed Res* 24(2) 100-106 DOI 10.1016/s1674-
335 8301(10)60017-6.
- 336 Huang L, Yuan K, Liu J, Ren X, Dong X, Tian W, Jia Y. 2014. Polymorphisms of the TLR4
337 gene and risk of gastric cancer. *Gene* 537(1) 46-50 DOI 10.1016/j.gene.2013.12.030.
- 338 Kang J, Chang JY, Sun X, Men Y, Zeng H, Hui Z. 2018. Role of Postoperative Concurrent

- 339 Chemoradiotherapy for Esophageal Carcinoma: A meta-analysis of 2165 Patients. *J*
340 *Cancer* 9(3) 584-593 DOI 10.7150/jca.20940.
- 341 Kohtz PD, Halpern AL, Eldeiry MA, Hazel K, Kalatardi S, Ao L, Meng X, Reece TB, Fullerton
342 DA, Weyant MJ. 2019. Toll-Like Receptor-4 Is a Mediator of Proliferation in Esophageal
343 Adenocarcinoma. *Ann Thorac Surg* 107(1) 233-241 DOI
344 10.1016/j.athoracsur.2018.08.014.
- 345 Kutikhin AG, Yuzhalin AE, Volkov AN, Zhivotovskiy AS, Brusina EB. 2014. Correlation
346 between genetic polymorphisms within IL-1B and TLR4 genes and cancer risk in a
347 Russian population: a case-control study. *Tumour Biol* 35(5) 4821-4830 DOI
348 10.1007/s13277-014-1633-6.
- 349 Li J, Yin J, Shen W, Gao R, Liu Y, Chen Y, Li X, Liu C, Xiang R, Luo N. 2017. TLR4 Promotes
350 Breast Cancer Metastasis via Akt/GSK3 β / β -Catenin Pathway upon LPS Stimulation.
351 *Anat Rec (Hoboken)* 300(7) 1219-1229 DOI 10.1002/ar.23590.
- 352 Li X, Li H, Dong X, Wang X, Zhu J, Cheng Y, Fan P. 2018. Expression of NF- κ B and TLR-4 is
353 associated with the occurrence, progression and prognosis of esophageal squamous cell
354 carcinoma. *Int J Clin Exp Pathol* 11(12) 5850-5859.
- 355 Lin Y, Totsuka Y, He Y, Kikuchi S, Qiao Y, Ueda J, Wei W, Inoue M, Tanaka H. 2013.
356 Epidemiology of esophageal cancer in Japan and China. *J Epidemiol* 23(4) 233-242 DOI
357 10.2188/jea.je20120162.
- 358 Minmin S, Xiaoqian X, Hao C, Baiyong S, Xiaping D, Junjie X, Xi Z, Jianquan Z, Songyao J.
359 2011. Single nucleotide polymorphisms of Toll-like receptor 4 decrease the risk of
360 development of hepatocellular carcinoma. *PLoS One* 6(4) e19466 DOI
361 10.1371/journal.pone.0019466.
- 362 Moral Moral GI, Viana Miguel M, Vidal Doce Ó, Martínez Castro R, Parra López R, Palomo

- 363 Luquero A, Cardo Díez MJ, Sánchez Pedrique I, Santos González J, Zanfaño Palacios J.
364 2018. Postoperative complications and survival rate of esophageal cancer: Two-period
365 analysis. *Cir Esp* 96(8) 473-481 DOI 10.1016/j.ciresp.2018.05.002.
- 366 Pandey N, Chauhan A, Jain N. 2018. TLR4 Polymorphisms and Expression in Solid Cancers.
367 *Mol Diagn Ther* 22(6) 683-702 DOI 10.1007/s40291-018-0361-9.
- 368 Paone A, Galli R, Gabellini C, Lukashev D, Starace D, Gorlach A, De Cesaris P, Ziparo E, Del
369 Bufalo D, Sitkovsky MV, Filippini A, Riccioli A. 2010. Toll-like receptor 3 regulates
370 angiogenesis and apoptosis in prostate cancer cell lines through hypoxia-inducible factor
371 1 alpha. *Neoplasia* 12(7) 539-549 DOI 10.1593/neo.92106.
- 372 Sato Y, Motoyama S, Wakita A, Kawakita Y, Liu J, Nagaki Y, Nanjo H, Ito S, Terata K, Imai K,
373 Minamiya Y. 2020. High TLR4 expression predicts a poor prognosis after
374 esophagectomy for advanced thoracic esophageal squamous cell carcinoma. *Esophagus*
375 DOI 10.1007/s10388-020-00732-x.
- 376 Shi G, Wang C, Zhang P, Ji L, Xu S, Tan X, Li H. 2017. Donor Polymorphisms of Toll-like
377 Receptor 4 rs1927914 Associated with the Risk of Hepatocellular Carcinoma Recurrence
378 Following Liver Transplantation. *Arch Med Res* 48(6) 553-560 DOI
379 10.1016/j.arcmed.2017.11.011.
- 380 Song J, Kim DY, Kim CS, Kim HJ, Lee DH, Lee HM, Ko W, Lee G. 2009. The association
381 between Toll-like receptor 4 (TLR4) polymorphisms and the risk of prostate cancer in
382 Korean men. *Cancer Genet Cytogenet* 190(2) 88-92 DOI
383 10.1016/j.cancergencyto.2008.12.011.
- 384 Takeda K, Umezawa R, Takahashi N, Matsushita H, Kozumi M, Ishikawa Y, Yamamoto T,
385 Takeda K, Jingu K. 2018. Impact of change in serum albumin level during and after
386 chemoradiotherapy in patients with locally advanced esophageal cancer. *Esophagus* 15(3)
387 190-197 DOI 10.1007/s10388-018-0612-1.

- 388 Terme M, Tanchot C. 2017. [Immune system and tumors]. *Ann Pathol* 37(1) 11-17 DOI
389 10.1016/j.annpat.2016.12.004.
- 390 Tsilidis KK, Helzlsouer KJ, Smith MW, Grinberg V, Hoffman-Bolton J, Clipp SL, Visvanathan
391 K, Platz EA. 2009. Association of common polymorphisms in IL10, and in other genes
392 related to inflammatory response and obesity with colorectal cancer. *Cancer Causes*
393 *Control* 20(9) 1739-1751 DOI 10.1007/s10552-009-9427-7.
- 394 Vijay K. 2018. Toll-like receptors in immunity and inflammatory diseases: Past, present, and
395 future. *Int Immunopharmacol* 59 391-412 DOI 10.1016/j.intimp.2018.03.002.
- 396 Wang K, Wang J, Wei F, Zhao N, Yang F, Ren X. 2017. Expression of TLR4 in Non-Small Cell
397 Lung Cancer Is Associated with PD-L1 and Poor Prognosis in Patients Receiving
398 Pulmonectomy. *Front Immunol* 8 456 DOI 10.3389/fimmu.2017.00456.
- 399 Wu H, Gao H, Li A, Xie Y, Jia Z, Yang Z, Zhang H, Zhang Z, Zhang X. 2020. Impact of
400 Genetic Variation in TLR4 3'UTR on NSCLC Genetic Susceptibility. *J Oncol* 2020
401 7593143 DOI 10.1155/2020/7593143.
- 402 Yang CS, Chen X, Tu S. 2016. Etiology and Prevention of Esophageal Cancer. *Gastrointest*
403 *Tumors* 3(1) 3-16 DOI 10.1159/000443155.
- 404 Yu C, Tang H, Guo Y, Bian Z, Yang L, Chen Y, Tang A, Zhou X, Yang X, Chen J, Chen Z, Lv
405 J, Li L. 2018. Hot Tea Consumption and Its Interactions With Alcohol and Tobacco Use
406 on the Risk for Esophageal Cancer: A Population-Based Cohort Study. *Ann Intern Med*
407 168(7) 489-497 DOI 10.7326/m17-2000.
- 408 Yue C, Li M, Da C, Meng H, Lv S, Zhao X. 2017. Association between genetic variants and
409 esophageal cancer risk. *Oncotarget* 8(29) 47167-47174 DOI 10.18632/oncotarget.17006.
- 410 Zhao S, Sun M, Meng H, Ji H, Liu Y, Zhang M, Li H, Li P, Zhang Y, Zhang Q. 2019. TLR4
411 expression correlated with PD-L1 expression indicates a poor prognosis in patients with

412 peripheral T-cell lymphomas. *Cancer Manag Res* 11 4743-4756 DOI
413 10.2147/cmar.S203156.

414

415 Figure 1: Transient reporter gene expression assays. Luciferase expression of two constructs
416 (pGL3-rs1927914G and pGL3-rs1927914A) in KYSE30 cells co-transfected with pRL-SV40 to
417 standardize transfection efficiency. Fold increase was measured by defining the activity of the
418 empty pGL-3 Basic vector as 1. *P < 0.05.

Table 1 (on next page)

Distributions of select characteristics in cases and control subjects

1

2

Table 1 Distributions of select characteristics in cases and control subjects

| Variables | case (n = 480) | | | Controls (n = 480) | | | P value ^a |
|-----------------------------------|----------------|------|---|--------------------|------|---|----------------------|
| | No | (%) | □ | No | (%) | □ | |
| Sex | | | | | | | 0.930 |
| Male | 403 | 84.0 | | 402 | 83.7 | | |
| Female | 77 | 16.0 | | 78 | 16.3 | | |
| Age | | | | | | | 0.162 |
| ≤50 | 83 | 17.3 | | 100 | 20.8 | | |
| >50 | 397 | 82.7 | | 380 | 79.2 | | |
| Smoking status | | | | | | | <0.001 |
| Non-smoker | 171 | 35.6 | | 333 | 69.4 | | |
| Smoker | 309 | 64.4 | | 147 | 30.6 | | |
| Pack year of smoking ^b | | | | | | | |
| ≤25 | 123 | 39.8 | | 69 | 46.9 | | 0.149 |
| >25 | 186 | 60.2 | □ | 78 | 53.1 | | |

3 ^aTwo-sidde χ^2 test

4

5

6

Table 2 (on next page)

Gene polymorphism of TLR4 and their association with ESCC

1

2

Table 2 Gene polymorphism of TLR4 and their association with ESCC

| TLR4 genotypes | Cases (n = 480) | | □ | Controls (n = 480) | | OR (95%CI) | P value ^a |
|----------------|-----------------|------|---|--------------------|------|------------------|----------------------|
| | No | (%) | | No | (%) | | |
| Rs1927914 | | | | | | | |
| AA | 195 | 40.6 | | 169 | 35.2 | | |
| GA | 237 | 49.4 | | 238 | 49.6 | 0.91(0.68-1.22) | 0.528 |
| GG | 48 | 10.0 | □ | 73 | 15.2 | 0.59(0.38-0.93) | 0.023 |
| Rs11536891 | | | | | | | |
| TT | 410 | 85.4 | | 410 | 85.4 | | |
| CT | 64 | 13.3 | | 68 | 14.2 | 0.96(0.65-1.43) | 0.847 |
| CC | 6 | 1.3 | | 2 | 0.4 | 4.59(0.87-24.25) | 0.073 |

3

^aData were analyzed by unconditional logistic regression and adjusted for sex, age and smoking status

4

Table 3 (on next page)

Stratified analysis between TLR4 rs1927914 genotypes and ESCC risk

1

2

Table 3 Stratified analysis between TLR4 rs1927914 genotypes and ESCC risk.

| Variables | Genotypes (Cases/Controls) | | | GG/AA model | GA/AA model |
|----------------------|----------------------------|---------|-------|-------------------------|-------------------------|
| | AA | GA | GG | OR (95%CI) ^a | OR (95%CI) ^a |
| Sex | | | | | |
| Male | 195/142 | 237/197 | 48/63 | 0.67(0.41-1.09) | 0.95(0.69-1.32) |
| Female | 35/27 | 38/41 | 4/10 | 0.31(0.09-1.11) | 0.73(0.37-1.44) |
| Age | | | | | |
| ≤50 | 38/33 | 34/52 | 11/15 | 0.53(0.18-1.55) | 0.55(0.26-1.17) |
| >50 | 157/136 | 203/186 | 37/58 | 0.59(0.36-0.97)* | 1.00(0.73-1.38) |
| Smoking status | | | | | |
| Non-smoker | 73/109 | 86/170 | 12/54 | 0.36(0.18-0.73)* | 0.76(0.51-1.13) |
| Smoker | 122/60 | 151/68 | 36/19 | 0.93(0.49-1.76) | 1.12(0.73-1.71) |
| Pack year of smoking | | | | | |
| ≤25 | 49/28 | 61/35 | 13/6 | 1.26(0.43-3.68) | 0.98(0.53-1.84) |
| >25 | 73/32 | 90/33 | 23/13 | 0.78(0.35-1.74) | 1.26(0.70-2.26) |

3

^aData were analyzed by unconditional logistic regression and adjusted for sex, age and smoking status

4

* $P < 0.05$

5

Table 4 (on next page)

Transient reporter gene expression assays

